Oppenheimer analyst Steven Lichtman reiterated an Outperform rating and $145.00 price target on DexCom (NASDAQ: DXCM) after non-insulin CGM was ...

This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE